XML 17 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Revenues:        
Clinical treatment programs - US $ 50 $ 42 $ 90 $ 91
Total Revenues 50 42 90 91
Costs and Expenses:        
Production costs 8 16
Research and development 1,145 2,953 3,096 5,005
General and administrative 2,591 2,550 6,406 4,841
Total Costs and Expenses 3,744 5,503 9,518 9,846
Operating loss (3,694) (5,461) (9,428) (9,755)
Gain (Loss) on investments (85) (94) (177) 109
Interest and other income 2,580 318 2,661 517
Interest expense and other finance costs (179) (251)
(Loss) on sale of fixed assets (23)
(Loss) on warrant issuance (458) (458)
Gain from sale of income tax operating losses 328 582
Net Loss $ (1,836) $ (4,909) $ (7,653) $ (8,570)
Basic loss per share $ (0.03) $ (0.10) $ (0.15) $ (0.18)
Diluted loss per share $ (0.03) $ (0.10) $ (0.15) $ (0.18)
Weighted average shares outstanding basic 52,837,477 48,411,251 51,161,956 48,405,675
Weighted average shares outstanding diluted 52,837,477 48,411,251 51,161,956 48,405,675